United States · 
What does Biogen Idec invest in?
Biogen Idec invests most often at Series A and Series B (70% of the rounds on record), in sectors such as Pharma, Cgt and Molecules.
Biogen Idec highlights
- 01
10 rounds on record
- 02
Mostly Series A and Series B: 70% of its rounds
- 03
Sole investor in 2 rounds, median $3.8M
- 04
3 exits from the portfolio
What they do
- Type
- VC firm (from a list, unverified)
- Cheque size
- Not stated
- Stages
- SeedSeries ASeries BGrowth
- Sectors
- PharmaCgtMolecules
- Based in
- Weston, United States
- Cold pitches
- Not stated
The record
Every round we can evidence, newest first10 appearances
- 2017
1 round
- Mar
- 2015
1 round
- Nov
- 2014
1 round
- Mar
- 2012
1 round
- Sept
- 2010
1 round
- Nov
- 2009
2 rounds
- Nov
- Jul
- 2008
2 rounds
- Mar
- Jan
- 2005
1 round
- Oct
An announcement gives the size of the round, not the size of this investor's cheque: the only rounds that imply a cheque are those where they were the sole named investor.
The team
We hold 2 people at this firm from the lists this database was built from: a weaker source than the filings, since a list does not say when a title ended. Login to see them.
What they claim to have backed
Weaker than a round we watched, stronger than a list somebody sold us. A firm is far less willing to put a company on its own site that it never funded.
Exits from the portfolio
Companies it backed that were later bought or listed3 in all
iPierianBought by Bristol-Myers Squibb$175MApr 2014
IntellikineBought by Takeda Pharmaceutical$310MDec 2011
Raven BiotechnologiesBought by MacroGenicsUndisclosedJul 2008
An exit counts when it came after the firm's first round in the company. From historical deal records.
Companies it bought
Acquisitions by the firm itself
Convergence Pharmaceuticals$675MJan 2015
Stromedix$750MFeb 2014
Tysabri$3.3BFeb 2013
Syntonix$120MJan 2007